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T 
HE terms programmed cell death (PCD) 1 and apop- 
tosis  are  often  used  interchangeably to  describe  a 
mechanism of cellular demise that is believed to play 
an important role in a wide variety of physiological situa- 
tions, and that when dysregulated can contribute to the patho- 
genesis of many diseases ranging from cancer to AIDS. Re- 
cently, the bcl-2 gene has emerged as a critical regulator of 
PCD in a variety of physiological and pathological contexts. 
Discovery of bcl-2 and Its Involvement in 
t(14:18) Translocations 
Bcl-2 is the acronym for the B-cell lymphoma/leukemia-2 
gene. As implied by its name, this gene was first discovered 
because of its involvement in B-cell malignancies, where 
chromosomal translocations activate the gene in the majority 
of follicular non-Hodgkin's B-cell lymphomas (Tsujimoto et 
al., 1985).  In these translocations, the bcl-2 gene is moved 
from its normal chromosomal location at  18q21 into jux- 
taposition with powerful enhancer elements in the immuno- 
globulin heavy-chain (IgH) locus at 14q32,  with the result 
being deregulation of the translocated bcl-2 gene and over- 
production  of bci-2  mRNAs  and  their  encoded proteins 
(reviewed by Nowell and Croce,  1987).  Though originally 
thought to occur only in the setting of malignant lymphoma, 
use of polymerase chain reaction (PCR) methods capable of 
detecting t(14;18) chromosomes in as few as 1 in 106 cells 
suggests that this translocation commonly arises in rare cells 
in the setting of the benign follicular hypertrophy of lymph 
nodes and tonsils (33-54%  of cases) that occurs during in- 
fections (Limpens et al.,  1991; Aster et al.,  1992).  Fortu- 
nately, the presence of  a t(14;18) in this circumstance appears 
to be insufficient by itself to lead to malignant lymphoma in 
the vast majority of cases, but nevertheless illustrates the 
malignant potential that perhaps exists in all of us. 
Bcl-2 Blocks a Final Common Pathway:for 
Programmed Cell Death 
Vaux et al. (1988) were the first to report that bcl-2 can pro- 
long cell survival. Using immature pre-B-cells that are de- 
pendent on the lymphokine Interleukin-3 (IL-3)  for their 
growth and survival in culture, these investigators noticed 
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1. Abbreviation  used in this paper:  PCD, programmed cell death. 
that stable transfer of bcl-2  expression vectors permitted 
prolonged cell survival in the absence of IL-3, but without 
concomitant cell proliferation (Vaux et al.,  1988).  Since it 
was known that IL-3 and several other Colony Stimulating 
Factors help to maintain hemopoietic cell survival in vitro 
by preventing apoptosis (Tushinski et al.,  1982;  Loten and 
Sachs,  1989; Williams et al.,  1990),  these results obtained 
with IL-3-dependent hemopoietic cells suggested that Bcl-2 
was capable of blocking PCD-a notion that was formally 
demonstrated by Hockenbery et al. (1990). Recent studies of 
bcl-2 function in cultured postmitotic neurons have further 
established a role for this gene in the suppression of PCD, 
in  complete  absence  of  cell  proliferation.  Specifically, 
microinjection  of bcl-2  expression  plasmids  into  Nerve 
Growth Factor (NGF)-dependent sympathetic neurons and 
into NGF-dependent or brain-derived neurotrophic factor 
(BDNF)-dependent central nervous system (CNS)-derived 
sensory neurons has been shown to markedly delay the rate 
of cell death that occurs upon removal of the neurotrophic 
factors from cultures (Garcia et al.,  1992;  Allsopp et al., 
1993).  In contrast to the prolonged cell survival observed 
when elevations in the levels of Bcl-2 protein are achieved 
through gene transfer methods, antisense-mediated reduc- 
tions in bcl-2 gene expression have been shown to accelerate 
the rate of cell death in the setting of growth factor with- 
drawal  (Reed  et  al.,  1990a,b),  thus  fulfilling another of 
Koch's postulates and confirming the importance of bcl-2 in 
the regulation of cell survival. Antisense experiments have 
additionally demonstrated that marked reductions in Bcl-2 
protein levels, though rendering ceils more prone to apopto- 
sis, are by themselves often insufficient  for causing cell death 
(Reed et al., 1990a,b; Kitada et al., 1993): a finding that is 
consistent with the observation that several types of cells do 
not contain detectable Bcl-2 protein in vivo (Hockenbery et 
al.,  1991; LeBrun et al.,  1993;  Lu et al.,  1993). 
The ability of  Bcl-2 protein over-production to prevent cell 
death without necessarily affecting cellular proliferation sug- 
gests  that the  bcl-2  gene defines a  new  category of on- 
cogenes. If one thinks of the cancer problem as a  simple 
balanced equation where: 
Rate of Cell  =  [Rate of Cell  _  Rate of Cell] 
Accumulation  [Proliferation  Death  ] 
then, it becomes immediately obvious that one can arrive at 
a condition of excess cells by either increasing the rate at 
which cells divide or by decreasing the frequency with which 
they die. Since cell death is a normal homeostatic mecha- 
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Causes of cell death that Bcl-2 has been documented to block: 
Chemotherapeutic drugs 
Gamma- and UV-radiation 
Heat shock 
Some viruses (Sindbis, 
Baculo) 
Free-radicals 
Lipid Peroxidation 
p53~ 
c-Myc 
Tumor Necrosis Factor 
Glutamate~ 
Calcium 
Glucose deprivation 
Growth Factor Deprivation 
Neurotrophic Factor Withdrawal 
TGF-beta~ 
Some cytolytic T-cells~ 
Azide 
Ced 9 gene mutants in C-Elegans 
Hydrogen Peroxide 
Documented causes of cell death that Bcl-2 does not block: 
Complement-mediated lysis 
Some cytolytic T-cells 
Amyloid fl peptide* 
Tumor Necrosis Factor 
Withdrawal of some lymphokines 
Anti-Ig and TCR (positive and negative thymic selection)~§ 
Hydrogen Peroxide 
Some types of neutrophic factor-dependent  neurons (CNTF) 
* Some inducers of cell death appear on both lists, thus representing  conflicts 
within  the literature.  Cell death induced  by complement, cytolytic  T-cells, 
amyloid ~ protein, TNF, and H202 often involves necrotic  cell death. 
Unpublished  observations  (J.  C. Reed). 
§ A weak effect on negative selection has been seen in some transgenic  lines. 
nism that exists in essentially all tissues with capacity for 
self-renewal and which helps to ensure that the rate of new 
cell production in the body is offset by a commensurate rate 
of old cell death,  it stands to reason that Bcl-2 and other 
genes that regulate the cell death side of the equation are at 
least as important as classical oncogenes which primarily ex- 
ert their effect by accelerating the rate of cell proliferation. 
In addition to delaying cell death in the setting of growth 
factor or neurotrophic factor withdrawal, over-expression of 
bcl-2 can prevent or markedly reduce cell killing induced by 
a wide variety of stimuli (summarized in Table I). In all cases 
where examined, Bcl-2 appeared to block a relatively early 
event associated with apoptotic cell death in that none of the 
characteristic morphological changes such as cell shrinkage, 
chromatin  condensation,  and  nuclear  fragmentation  oc- 
curred, and DNA degradation into oligonucleosomal length 
fragments was markedly reduced or prevented. Though few 
mechanistic details are known at this point, these data have 
suggested that bcl-2 blocks a final common pathway leading 
to apoptotic cell death. The participants in this pathway re- 
main unknown, but the observation that bcl-2 blocks apopto- 
sis induced by multiple chemotherapeutic drugs as well as 
3'-irradiation provides some clues that may help to provide 
at least a  partial explanation (Miyashita and Reed,  1992, 
1993; Lotem and Sachs,  1993; Fanidi et al.,  1992;  Collins 
et al.,  1992; J. C. Reed, unpublished observations). For ex- 
ample, 3,-irradiation and the wide variety of drugs to which 
Bcl-2 confers resistance have diverse mechanisms of action, 
but all induce DNA damage either directly or indirectly. The 
protection afforded by Bcl-2 does not involve reductions in 
drug-induced damage to DNA, increased rates of DNA re- 
pair,  inhibition  of drug-induced  alterations  in  nucleotide 
pools, or changes in cell cycle kinetics (Walton et al.,  1993; 
Fisher et al.,  1993). Thus, Bcl-2 appears to act downstream 
of all  of these events, perhaps preventing the presence of 
damaged DNA from being translated into a signal for activa- 
tion of  the genes involved in apoptosis, or blocking the action 
of the products of those genes once induced.  One of the 
mediators of this pathway could be the tumor suppressor p53 
which has been implicated in genomic surveillance, under- 
goes increases in its protein levels and activity in response 
to  drug-induced  DNA  damage  (Zhan  et  al.,  1993),  and 
which can induce apoptosis under a  variety of conditions 
(reviewed by Sachs and Lotem, 1993). It is tempting to spec- 
ulate therefore that a functional connection between p53 and 
Bcl-2 may exist. Indeed, preliminary indications are that the 
gene transfer-mediated over-production of Bcl-2 protein can 
partially suppress p53-induced apoptosis,  at least in some 
hemopoietic cell lines (Wang et al., 1993). Clearly, however, 
p53 is not the whole story where Bcl-2 and the regulation 
of apoptosis are concerned, since recent investigations using 
p53  "knock-out" mice indicate that this tumor suppressor 
gene is required for induction of apoptosis by some stimuli 
such as 3"-irradiation and etoposide (VP16) but not by gluco- 
corticoids and Ca2Monophores in thymocytes (Lowe et al., 
1993; Clark et al.,  1993), and yet it is known that Bcl-2 is 
very effective at blocking glucocorticoid- and Ca2+-induced 
cell death (Sentman et al., 1991; Strasser et al., 1991; Siegel 
et al.,  1992;  Miyashita and Reed,  1992,  1993). 
The identity of other proteins that might help to regulate 
the induction of genes required for PCD in the absence of 
p53 are at present unknown, but p62-c-myc is a potential can- 
didate given evidence that it can accelerate the rate of apop- 
tosis in a variety of settings (Asken et al.,  1991; Evan et al., 
1992;  Shi  et  al.,  1992).  Gene transfer experiments have 
shown that bcl-2 blocks apoptosis induced by c-myc (Bisson- 
nette et al.,  1992; Fanidi et al.,  1992), suggesting an expla- 
nation for the aggressive nature of lymphomas and leukemias 
that contain chromosomal translocations involving both of 
these genes. Namely, since c-myc stimulates both mitogene- 
sis and apoptosis, concomitant activation ofbcl-2 can nullify 
the apoptotic influence of c-myc, thus unleashing the prolif- 
erative effects of c-myc and leading to a  further selective 
growth advantage. Even in the absence of concomitant c-myc 
gene activation, however, bcl-2 expression appears to confer 
a worse prognosis on patients with at least some types of  can- 
cer, based on clinical correlative studies where the presence 
of either the Bcl-2 protein or bcl-2 gene rearrangements has 
been associated with poor responses to therapy in patients 
with non-Hodgkin's lymphomas, acute myelogenous leuke- 
mia, and prostate cancer (Yunis et al.,  1989; Campos et al., 
1993; McDonnell et al.,  1992). 
Though centrally involved in the suppression of apoptosis, 
bcl-2 overexpression fails to protect cells in some circum- 
stances from what appears to be apoptotic death (see Table 
I). Of course, it is possible that some of these routes to cellu- 
lar demise that Bcl-2 fails to block are in fact more consistent 
with necrotic than apoptotic cell death, but this is not uni- 
formly the case. Thus, either Bcl-2 alone is insufficient to 
prevent all forms of apoptotic cell death, or there exist Bcl-2- 
independent pathways for regulating PCD. Given that some 
tissues such as the liver lack bcl-2 expression altogether, and 
yet are subject to regulation by apoptosis (Oberhammer et 
al., 1992), Bcl-2-independent mechanisms clearly do exist. 
The recent discovery of proteins that share sequence homol- 
ogy with Bcl-2 and that can repress its apoptosis-blocking 
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why over-expression ofbcl-2 is ineffective at preventing PCD 
in some types of cells and circumstances (Boise et al., 1993; 
Oltari et al.,  1993). 
Structure of  Bcl-2 and Related Proteins 
The amino-acid sequence of the 25-26 kD Bcl-2 protein, as 
predicted from eDNA cloning, contains no sequence motifs 
that might suggest a biochemical function for this regulator 
of PCD. The most noteworthy structural feature in the pro- 
teins from humans, mice, rats, and chickens is a stretch of 
19 hydrophobic amino acids near the COOH terminus fol- 
lowed by just two charged residues that presumably serve to 
anchor  the  protein  in  membranes  (Cazals-Hatem  et  al., 
1992;  Sato et al.,  1993).  Mutagenesis studies have con- 
firmed that the hydrophobic COOH-terminal region allows 
posttranslational insertion  into  membranes  such  that the 
bulk of the Bcl-2 protein  should be oriented towards the 
cytosol (Chert-Levy and Cleary,  1990),  and have demon- 
strated the importance of membrane insertion for Bcl-2's 
function as a blocker of apoptosis (Hockenbery et al., 1990; 
Tanaka et al., 1993). A second shorter form of the Bcl-2 pro- 
tein that lacks a hydrophobic tail can potentially be produced 
through alternative splicing (Tsujimoto and Croce,  1986), 
but this protein (termed Bcl-2/3) has never been seen in vivo 
in any appreciable amounts. 
Cleary et al. (1986) were the first to notice that Bcl-2 has 
weak homolog (22 % identity; 42 % similarity) with an open 
reading  frame in  the  Epstein  Barr  Virus  (EBV),  termed 
BHRF-1. Like Bcl-2, the BHRF-1 protein has a hydrophobic 
tail,  is associated with intracellular membranes,  and can 
block programmed cell death caused by growth factor depri- 
vation in human and murine hematolymphoid cells (Hender- 
son et ai., 1993; Takayama et al., 1993). The importance of 
these findings is in their demonstration that viruses can har- 
bor Bcl-2 homologs which are capable of inhibiting PCD. 
When taken together with the observation that Bcl-2 can in 
some cases  block or delay the  apoptotic death of virus- 
infected cells and convert a lytic viral infection into a non- 
lytic persistent infection (Levine et al., 1993; Alnemri et al., 
1992), the results suggest the possibility that virally encoded 
Bcl-2 homologs could perhaps contribute to viral latency or 
allow for persistent infections in the absence of cell lysis. 
Moreover, the recent discovery that the LMW5-HL protein 
of African Swine Fever virus has 26 % homology (47 % sim- 
ilarity) with Bcl-2 suggests that viral-regulators of the Bcl-2 
pathway are not limited to EBV (Neilan et al., 1993). Of fur- 
ther interest with regards to viruses,  EBV  contains addi- 
tional genes that can indirectly upregulate expression of the 
human bcl-2 gene in B-cells (Henderson et al.,  1991; Finke 
et al.,  1992),  thus providing another example of a mecha- 
nism that potentially can be utilized by viruses to prevent 
host cell death. 
Recently, cDNAs have been cloned for several novel hu- 
man genes, revealing a family of Bcl-2-related proteins. One 
of these, termed Bcl-X, encodes a 241-amino acid protein 
with 74% homology to Bcl-2 and that in preliminary gene 
transfer experiments functions essentially interchangeably 
with Bcl-2 to promote cell survival. An alternatively splice 
form of Bcl-X lacks a 63-amino acid region that is extremely 
well conserved among Bcl-2 homologs and inhibits Bcl-2 
function (Boise et al.,  1993).  An additional Bcl-2 homolog 
called  Bax  was  discovered  through  analysis  of  Bcl-2- 
associated proteins. A 21-kD (192 amino acids) isoform of 
Bax contains a transmembrane domain, has 21% homology 
(43 % similarity) with Bcl-2, and appears to form heterodi- 
mers with the Bcl-2 protein an inactivate it (Oltari et al., 
1993). The existence of Bcl-2/Bax heterodimers implies that 
Bcl-2 functions as a homodimer or oligomer, though bio- 
chemical evidence either supporting or opposing this idea is 
lacking at this time. Given that the Bcl-2-ot and Bax-ot pro- 
teins are 21% homologous (43 % similarity when conserva- 
tive replacements are permitted), it seems likely that much 
insight into Bcl-2 protein structure-function relations could 
be  gained  by  creating  chimeric  Bcl-2/Bax  proteins  and 
thereby mapping the regions within Bcl-2 and Bax differen- 
tially responsible for suppression and acceleration of apop- 
tosis, respectively. In contrast to Bax, the short form of  Bcl-2 
(Bcl-X-S) reportedly does not bind to the Bcl-2 protein and 
therefore presumably inhibits by competing either for un- 
known  effector proteins  that  interact  with  Bcl-2  and  lie 
downstream of it or for upstream activators of the Bcl-2 
protein. 
Additional members of the bcl-2 family termed mcl-1 and 
A1 were fortuitously  identified through differential screening 
of eDNA libraries derived from myeloid leukemic and nor- 
mal cells, respectively, induced to differentiate. Mcl-1 en- 
codes a 37-kD protein that contains a stretch of 139 amino 
acids with 35 % homology (59% similarity) with the corre- 
sponding region of human p26-Bcl-2 (Kozopas et al., 1993). 
A1 encodes a ~20-kD protein that has 40% overall homol- 
ogy with Bcl-2 over a stretch of 80 amino acids in the car- 
boxyl  half of the  A1  protein  (Lin  et  al.,  1993).  Mcl-1 
topographically resembles Bcl-2 with regards to having a hy- 
drophobic domain near the COOH terminus but the corre- 
sponding  segment in  A1  contains a  charged residue that 
makes it a poorer candidate for an integral membrane pro- 
tein. The functions of Mcl-1 and A1 have not been reported 
to date. Whether other mammalian genes exist that share se- 
quence and functional homology with Bcl-2  remains un- 
known, but considering that several tissues that are subject 
to regulation by PCD lack expression of bcl-2 and known 
related genes, it seems likely that additional members of the 
bcl-2 gene family will eventually be discovered.  Further- 
more, the finding that one of the members of the Bcl-2 pro- 
tein family, Bax, can form heterodimers with Bcl-2 raises 
interesting possibilities with regards to potential combinato- 
rial interactions among the various members of the Bcl-2 
family. 
lntracellular Locations and Potential Mechanisms of 
Action of Bcl-2 Protein 
In the absence of any knowledge of the biochemical action 
of Bcl-2,  considerable efforts have been expended on ex- 
amining the subcellular location of this oncoprotein in the 
hope that such information would provide some clues. The 
most recent observations based on use of confocal, laser 
scanning, and electron microscopy suggest that Bcl-2 resides 
in the nuclear envelope, parts of the endoplasmic reticulum 
(ER), and outer mitochondrial membrane but not in a variety 
of other intracellular membrane compartments including the 
plasma membrane (Monaghan et al., 1992; Jacobson et al., 
1993;  Krajewski  et  al.,  1993).  Subcellular  fractionation 
studies have also provided convincing evidence of Bcl-2's as- 
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Krajewski et al.,  1993), a finding that is consistent with the 
punctate cytosolic immunostaining seen at the level of the 
conventional light-microscope in cells subjected to immuno- 
staining using Bcl-2-specific antibodies. Based on differen- 
tial detergent extractions of outer and inner mitochondrial 
membranes, Hockenbery et al. (1990) concluded that Bcl-2 
is an  inner mitochondrial membrane protein, but the be- 
havior of Bcl-2 in in vitro mitochondrial import assays is 
more consistent with an outer membrane protein (Krajewski 
et al., 1993). One potential explanation for the apparent dis- 
crepancy could lie in the observation that the pattern of im- 
munostaining  seen at the EM level suggests that Bcl-2 is 
present in a  patchy, non-uniform distribution in the outer 
membrane, suggestive of the junctional complexes where in- 
ner and outer membranes abut. 
The localization of Bcl-2 to mitochondria prompted an ex- 
amination of the relevance of oxidative phosphorylation to 
Bcl-2 protein function. Using a human fibroblast cell line 
that had been depleted of its mitochondrial DNA by growth 
in  media  containing  ethidium  bromide,  Jacobson  et  al. 
(1993) showed that no apparent requirement exists for oxida- 
tive phosphorylation for either induction of apoptosis or for 
Bcl-2 to function as a suppressor of cell death.  Consistent 
with these data,  no effect of Bcl-2 protein over-production 
was found on ATP levels or oxygen consumption in PC12 
cells despite their resistance to induction of apoptosis by a 
wide  variety of stimuli  (Mah  et al.,  1993;  Zhong et al., 
1993). Similarly, Hennet et al. (1993) reported that transfec- 
tion of bcl-2 expression constructs in L929 mouse fibrosar- 
coma cells did not affect oxygen consumption or the activity 
of the mitochondrial respiratory chain, but did appear to in- 
crease the mitochondrial membrane potential-at least as 
defined by crude measurements involving uptake of Rhoda- 
mine  123 into intact cells. 
In contrast to the mitochondria, only scant efforts have 
been made thus far to evaluate the function of Bcl-2 in the 
nuclear envelope and ER compartments. Recent EM data 
suggest that Bcl-2 protein is not randomly distributed in the 
membranes of the nuclear envelope but rather is concen- 
trated in patches highly reminiscent of nuclear pore com- 
plexes (NPCs) (Krajewski et al.,  1993). If true, the finding 
raises the possibility of a role for Bcl-2 in some aspect of nu- 
clear transport, NPC formation, or nuclear envelope assem- 
bly  and  maintenance.  Double-labeling  studies  at the EM 
level are needed however to confirm the precise relation, if 
any, of Bcl-2 to NPCs.  Still another possibility stems from 
the fact that the space between the inner and outer nuclear 
membranes, in its continuity with the lumen of the ER, is 
the major intracellular storage site for Ca  2+.  A  variety of 
data  have suggested that  Ca  2+ plays  an  important role in 
apoptosis, and several groups have characterized nucleus- 
associated Ca2+-dependent  endonucleases that may be in- 
volved in  the  internucleosomal DNA digestion typical of 
apoptotic cells. In this regard, Bcl-2 has been shown to block 
apoptosis induced by Ca2+-ionophores in thymocytes, T-cell 
leukemia lines, and PC12 cells. Fluorometric measurements 
of cytosolic free Ca  2+ concentrations in ionophore-treated 
PC12 cells have revealed that over-production of Bcl-2 does 
not prevent rises in intracellular Ca  2+, suggesting that Bcl-2 
blocks an apoptotic signal downstream of this event (Zhong 
et al.,  1993). Baffy et al. (1993) also examined the calcium 
issue, focusing on the stores of Ca  2+ sequestered in the ER 
and  in mitochondria in IL-3-dependent cells deprived of 
lymphokine.  Factor  withdrawal  led  to  a  gradual  loss  of 
Ca  2+ from the ER and a rise in the relative amounts of Ca  2+ 
in the mitochondria. Gene transfer-mediated elevations in 
Bcl-2  protein prevented the  alterations  in  Ca  2+  and  sup- 
pressed apoptotic cell death. These data suggest that Bcl-2 
either directly or indirectly can influence Ca  2+ partitioning, 
• but the question now is  whether those alterations in Ca  z+ 
contribute functionally to the apoptotic process. In support 
of this possibility are the observations that:  (a) glucocorti- 
coid-treatment of T-cells has also been shown to result in a 
massive loss of Ca  2+ from the ER prior to apoptotic cell 
death, suggesting that depletion of the ER pool of Ca  2+ may 
be a  common theme;  (b)  over-expression of an  ER Ca  2+ 
binding protein calbindin D28K in glucocorticoid sensitive 
T-cells delays apoptosis induced by dexamethasone, forsko- 
lin and A23187, presumably by allowing the ER to better re- 
tain its Ca2+;  and (c) poisoning the Ca2+-ATPase of the ER 
with  thapsigargin  induces  apoptosis  (Lam  et  al.,  1993; 
Dowd et al.,  1992). Thus, a connection between Bcl-2 and 
Ca  2+  regulation  makes  an  attractive  hypothesis  that  fits 
nicely with the literature on Ca2÷-dependent  endonucleases 
and apoptosis, but that requires much further investigation. 
An equally attractive hypothesis concerns the role of ox- 
idative injury in the induction of cell death and the finding 
that Bcl-2 blocks the accumulation of lipid peroxides, as well 
as possibly other reactive oxygen species in at least some set- 
tings (Kane et al.,  1993; Hockenbery et al.,  1993). Though 
these findings in mammalian ceils fall far short of establish- 
ing a direct cause and effect relation between Bcl-2 and con- 
trol of cellular redox, a compelling argument can be made 
based on experiments performed in S. cerevisiae deficient in 
Mn-Superoxide Dismutase where expression of Bcl-2 was 
reported to restore growth in conditions requiring respira- 
tory metabolism (Kane et al.,  1993). 
Clearly, many questions remain unanswered regarding the 
biochemical mechanism of action by which the Bcl-2 protein 
protects cells from apoptotic cell death and the functional 
significance of its association with mitochondria,  nuclear 
envelope and ER. Given that several groups have recently 
cloned and are presently characterizing cDNAs that encode 
non-Bcl-2-related proteins that are capable of binding to the 
Bcl-2 protein (unpublished data and personal communica- 
tions), perhaps the answers to these questions will not be far 
off. In this regard, the recent demonstration that Bcl-2 can 
interact with R-Ras in the yeast two-hybrid system and evi- 
dence that the two proteins co-immunoprecipitate in mam- 
malian  cells  raises  interesting  possibilities  (Fernandez- 
Sarabia and Bischoff, 1993). The effector domain of R-Ras 
for example is predicted to be capable of interacting with the 
Raf kinase, and we have observed in gene transfer experi- 
ments that Bcl-2 and Raf oncogenes can act synergistically 
to suppress apoptosis  in some circumstances (manuscript 
submitted for publication). Thus, Bcl-2 may control a signal 
transduction  pathway  that,  among  other  things,  possibly 
could target signaling molecules to critical intracellular lo- 
cations such as mitochondrial junctional and nuclear pore 
complexes. Regardless of the validity of these speculations, 
it seems likely that when the answers to the Bcl-2 mystery 
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but will also provide critical insights into the still poorly un- 
derstood phenomenon of apoptosis. 
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